Target Price | $613.02 |
Price | $645.55 |
Deviation | 5.04% |
Number of Estimates | 16 |
16 Analysts have issued a price target IDEXX Laboratories 2026 . The average IDEXX Laboratories target price is $613.02. This is 5.04% lower than the current stock price. The highest price target is $824.25 27.68% , the lowest is $393.82 38.99% . | |
A rating was issued by 21 analysts: 14 Analysts recommend IDEXX Laboratories to buy, 7 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2026 of 5.04% . Most analysts recommend the IDEXX Laboratories stock at Purchase. |
17 Analysts have issued a sales forecast IDEXX Laboratories 2025 . The average IDEXX Laboratories sales estimate is $4.2b . This is 4.81% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.4b 9.05% , the lowest is $4.0b 0.07% .
This results in the following potential growth metrics:
2024 | $3.9b | 6.46% |
---|---|---|
2025 | $4.2b | 8.58% |
2026 | $4.6b | 7.68% |
2027 | $4.9b | 8.47% |
2028 | $5.3b | 7.00% |
2029 | $5.5b | 4.92% |
13 Analysts have issued an IDEXX Laboratories EBITDA forecast 2025. The average IDEXX Laboratories EBITDA estimate is $1.5b . This is 6.19% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.6b 14.66% , the lowest is $1.4b 0.63% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $1.3b | 4.09% |
---|---|---|
2025 | $1.5b | 17.12% |
2026 | $1.6b | 10.14% |
2027 | $1.8b | 9.39% |
2028 | $1.9b | 5.33% |
2029 | $2.0b | 4.16% |
2024 | 32.40% | 2.23% |
---|---|---|
2025 | 34.95% | 7.87% |
2026 | 35.75% | 2.29% |
2027 | 36.05% | 0.84% |
2028 | 35.49% | 1.55% |
2029 | 35.23% | 0.73% |
18 IDEXX Laboratories Analysts have issued a net profit forecast 2025. The average IDEXX Laboratories net profit estimate is $995m . This is 0.95% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $1.0b 6.04% , the lowest is $932m 5.49% .
This results in the following potential growth metrics and future Net Margins:
2024 | $888m | 5.07% |
---|---|---|
2025 | $995m | 12.07% |
2026 | $1.1b | 12.16% |
2027 | $1.3b | 12.79% |
2028 | $1.4b | 9.43% |
2029 | $1.4b | 2.20% |
2024 | 22.78% | 1.31% |
---|---|---|
2025 | 23.51% | 3.20% |
2026 | 24.49% | 4.17% |
2027 | 25.47% | 4.00% |
2028 | 26.05% | 2.28% |
2029 | 25.37% | 2.61% |
18 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories EPS is $12.41 . This is 2.06% higher than earnings per share in the financial year 2024. The highest EPS forecast is $13.04 7.24% , the lowest is $11.62 4.44% .
This results in the following potential growth metrics and future valuations:
2024 | $10.67 | 6.06% |
---|---|---|
2025 | $12.41 | 16.31% |
2026 | $13.93 | 12.25% |
2027 | $15.71 | 12.78% |
2028 | $17.19 | 9.42% |
2029 | $17.56 | 2.15% |
Current | 52.06 | 7.13% |
---|---|---|
2025 | 50.99 | 2.06% |
2026 | 45.46 | 10.85% |
2027 | 40.31 | 11.33% |
2028 | 36.83 | 8.63% |
2029 | 36.04 | 2.14% |
Based on analysts' sales estimates for 2025, the IDEXX Laboratories stock is valued at an EV/Sales of 12.19 and an P/S ratio of 11.97 .
This results in the following potential growth metrics and future valuations:
Current | 12.78 | 17.79% |
---|---|---|
2025 | 12.19 | 4.62% |
2026 | 11.32 | 7.13% |
2027 | 10.44 | 7.81% |
2028 | 9.75 | 6.54% |
2029 | 9.30 | 4.69% |
Current | 12.54 | 17.17% |
---|---|---|
2025 | 11.97 | 4.59% |
2026 | 11.11 | 7.13% |
2027 | 10.25 | 7.81% |
2028 | 9.58 | 6.54% |
2029 | 9.13 | 4.69% |
IDEXX Laboratories...
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 15 2025 |
Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Aug 11 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Aug 04 2025 |
Leerink Partners |
Outperform
➜
Outperform
|
Unchanged | Jul 17 2025 |
Stifel |
Hold
➜
Hold
|
Unchanged | Jul 02 2025 |
Leerink Partners |
Outperform
➜
Outperform
|
Unchanged | Jun 11 2025 |
Stifel |
Hold
➜
Hold
|
Unchanged | May 19 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 15 2025 |
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Aug 11 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Aug 04 2025 |
Unchanged
Leerink Partners:
Outperform
➜
Outperform
|
Jul 17 2025 |
Unchanged
Stifel:
Hold
➜
Hold
|
Jul 02 2025 |
Unchanged
Leerink Partners:
Outperform
➜
Outperform
|
Jun 11 2025 |
Unchanged
Stifel:
Hold
➜
Hold
|
May 19 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.